title: Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
abstract: In April 2011, abiraterone acetate (AA) was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer (CRPC) after chemotherapy. The development of AA is the direct result of our increased understanding of the intricacies of the androgen receptor (AR) pathway and its natural evolution in prostate cancer cells over the course of treatment. In this paper we review the biology of the AR and how it led to the rational design of AA. We also examine the clinical development of AA, its current use, and questions to be addressed for future development.
authors: Department of Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
authors: A
authors: A
authors: Bryce
authors: C J
authors: CJ
authors: Ryan
mesh_terms: D000069501:Abiraterone Acetate; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000096:biosynthesis / Q000378:metabolism*; D000730:Androstadienes / Q000627:therapeutic use*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011944:Receptors, Androgen / Q000378:metabolism
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D011944:Receptors, Androgen; D000069501:Abiraterone Acetate